BioNTech, the German biotech which announced an apparent vaccine to coronavirus on Monday, is a classic European startup story: created by Turkish immigrants, funded by US and Asian investors and listed on the Nasdaq.
Along with pharma giant Pfizer, BioNTech is the first drug maker to show successful results from clinical trials of a coronavirus vaccine. Trials on thousands of volunteers found no serious safety concerns, meaning the companies will seek emergency use authorisation for the vaccine in the US later this month.